Naringin alleviates methotrexate-induced liver injury in male albino rats and enhances its antitumor efficacy in HepG2 cells

Hany Elsawy1,2, Abdulmohsen I. Algefare3, Manal Alfwuaires3, Mahmoud Khalil4,5, Omar M. Elmenshawy6, Azza Sedky3,5, Ashraf M. Abdel-Moneim3,5,*

1Department of Chemistry, Faculty of Science, King Faisal University, Al-Ahsa, Saudi Arabia
2Department of Chemistry, Faculty of Science, Tanta University, Tanta, Egypt
3Department of Biological Sciences, Faculty of Science, King Faisal University, Hofuf-31982, Al-Ahsa, Saudi Arabia.
4Department of Biological Sciences, Faculty of Science, Beirut Arab University, Lebanon
5Department of Zoology, Faculty of Science, Alexandria University, Alexandria, Egypt
6Department of Zoology, Faculty of Science, Al-Azhar University, Cairo, Egypt

*Corresponding Author:
Ashraf M. Abdel-Moneim

Department of Biological Sciences, Faculty of Science, King Faisal University, Hofuf-31982, Al-Ahsa, Saudi Arabia; Department of Zoology, Faculty of Science, Alexandria University, Alexandria, Egypt

Email:
aabdelmoneim@kfudem.com; ashraf.abdelmoneim@alexu.edu.eg

Orcid: https://orcid.org/0000-0002-0270-703X
Abstract:

Methotrexate (MTX) is an efficient chemotherapeutic and immunosuppressant drug, but the hepatotoxicity of MTX limits its clinical use. Naringin (Nar) is a flavonoid derived from Citrus paradisi, and has been shown to possess several pharmacological activities, including free-radical scavenging and antioxidant properties. In this study, we first tested the possible protective effects of multiple doses of Nar against MTX-induced acute hepatotoxicity in rats, and then we investigated the growth inhibition and apoptotic effects of MTX and/or Nar against the HepG2 hepatocarcinoma cell line. Our in vivo results showed that Nar significantly reduced MTX-induced increases in serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and total bilirubin levels. Nar also reduced MTX-induced oxidative stress by significantly reducing liver malondialdehyde and nitric oxide content and increasing superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione. In addition, Nar significantly counteracted MTX-induced increases in hepatic interleukin-6 and tumor necrosis factor-alpha. Further, Nar greatly protected hepatocyte ultrastructure against MTX-induced injury. In contrast, in vitro MTX and/or Nar treatment of HepG2 cells for 48 h exhibited a cytotoxic effect and induced apoptosis in a dose-dependent manner mediated by a significant increase in the Bax/Bcl-2 protein expression ratio. Noticeably, Nar potentiated the MTX effect on the Bax/Bcl-2 ratio. In conclusion, Nar decreased MTX-induced functional and ultrastructural liver damage in a tumor-free animal model. Also, our data introduce MTX and Nar as promising antiproliferative agents with a distinctive mode of action, inducing apoptosis in HepG2 tumor cells through activation of Bax and downregulation of Bcl-2 protein expression.

Keywords: Naringin, methotrexate, liver oxidative damage, HepG2 cells, Bax/Bcl-2 ratio
Introduction

Methotrexate (MTX), a folic acid antagonist, is widely used in the treatment and prophylaxis of several types of malignant tumors. However, MTX is known to induce liver damage in animals, and more than 10% of patients receiving MTX. Several studies have shown that MTX toxicity is mediated by oxidative stress and dysregulation of antioxidant defenses, thereby increasing the generation of reactive oxygen species (ROS) as superoxide anions, hydrogen peroxide and hydroxyl radicals. ROS formation can initiate lipid peroxidation (LPO) and the release of inflammatory mediators, including tumor necrosis factor-alpha (TNF-α) and inducible nitric oxide synthase (iNOS). TNF-α is a key factor in liver and kidney homeostasis. TNF-α activates proapoptotic (mainly caspases) and antiapoptotic (mainly NF-κB pathways). Increased expression of TNF-α has been reported in a model of MTX-induced hepatic, renal and intestinal damage. The proinflammatory effect of TNF-α is mediated through NF-κB-regulated proteins, such as iNOS and cyclooxygenase-2. Nitric oxide (NO) is a free radical molecule with a multitude of physiological functions. This highly reactive molecule is synthesized from L-arginine by a group of isoenzymes collectively termed NO synthases (NOS). The role of iNOS has been implicated in the pathogenesis of MTX-induced toxicity. Therefore, attenuation of oxidative stress can represent an effective strategy to protect against MTX-induced hepatotoxicity.

Recently, several reports have highlighted the role of antioxidants in preventing diseases through free radical scavenging mechanisms. Naringin (4′,5,7-trihydroxyflavanone-7-rhamnoglucoside) (Nar) is a bioflavonoid and polyphenolic compound that is found in grapefruit, orange and cooked tomato paste and is associated with citrus herb species.
Studies have shown that Nar has a broad spectrum of biological and pharmacological activities, including hepatoprotective,\textsuperscript{13} anticarcinogenic,\textsuperscript{14} antidiabetic,\textsuperscript{15} and anti-inflammatory effects.\textsuperscript{16}

According to the latest world cancer statistics published by the International Agency for Research on Cancer (IARC)-Global Cancer Observatory (GCO) (Globocan 2018), liver cancer is ranked fourth on the list of cancer-related deaths. Based on IARC statistics, the estimated number of deaths from liver cancer in 2018 is approximately 0.8 million deaths, and the mortality burden projections worldwide will be increased by 66% in 2040.\textsuperscript{17} Few reports have highlighted the effects of Nar in HepG2 cells, including restraining inflammatory markers such as c-reactive protein and TNF-\textgreek{a}, quenching NF-\kappa B and ERK1/2 activities,\textsuperscript{18} and inducing apoptosis via the mitochondrial pathway,\textsuperscript{19} and via the upregulation of miR-19b and Bax/Bcl-2 protein ratio expression.\textsuperscript{20} In addition, it has been reported that the antihyperglycemic effects of Nar in HepG2 cells are associated with the upregulation of phospho-AMP-activated protein kinase (pAMPK), a key enzyme in the regulation of cellular energy homeostasis.\textsuperscript{21,22} In a very recent study, the polymeric micellization of Nar with pluronic F-68, a nonionic surfactant, was shown to enhance the antitumor activity of Nar against HepG2, MCF-7, and Caco-2 cells. Furthermore, Nar–PF68 micelles inhibit tumor growth in Ehrlich ascites carcinoma-bearing mice.\textsuperscript{23} To the best of our knowledge, the dual effect of Nar and MTX on hepatocellular carcinoma has not been investigated. Considering the abovementioned data, first, we aimed to evaluate the protective potential of Nar on MTX-induced hepatotoxicity in a rat model. Second, we aimed to uncover the effect of the cotreatment of Nar and MTX on the HepG2 hepatocellular carcinoma cell line.
Material and methods

Animals and treatments

The animal work was conducted at King Faisal University (Al-Ahsa, Saudi Arabia).

Animal care and experimental procedures were approved and licensed by the research ethics committee at King Faisal University (reference number: KFU-REC/2019-03-05).

Male albino rats were obtained from an animal facility at the Faculty of Science, King Saud University, Saudi Arabia. Rats (220±30 g) were housed in stainless steel wire-bottomed cages and placed in a well-ventilated animal house, maintained for two weeks for to acclimatize with food and water ad libitum, and subjected to a natural 12 h light:dark cycle. Rats were divided randomly into five groups (n = 6 rats each) as follows:

- Control group: Rats received daily intraperitoneal (ip) administration of saline as a vehicle.
- MTX group: Rats received a single ip dose of MTX (20 mg/kg) on the fourth day of the experiment.
- MTX+ Nar20 group: Rats received a daily ip dose of Nar (20 mg/kg) and a single ip dose of MTX (20 mg/kg) on the fourth day of the experiment.
- MTX+ Nar40 group: Rats received a daily ip dose of Nar (40 mg/kg) and a single ip dose of MTX (20 mg/kg) on the fourth day of the experiment.
- MTX+ Nar80 group: Rats received a daily ip dose of Nar (80 mg/kg) and a single ip dose of MTX (20 mg/kg) on the fourth day of the experiment.

Nar (Cat. No. 71162) and MTX (Cat. No. M9929) have been purchased from Sigma-Aldrich, USA. The drugs were dissolved in DMSO/saline with the final concentration of 1% DMSO. The duration of the experiment was 10 days. MTX and Nar doses were selected according to previous reports.5,24,25

In vivo sample collection and biochemical assays

At the end of the experimental period, rats were anesthetized with diethyl ether and sacrificed by cervical dislocation. Blood samples were collected immediately, and sera were obtained after centrifugation at 1,000 xg for 20 min and stored at −80°C until use. Serum levels of hepatic function markers were determined using commercial kits (Human Assay Kits, Wiesbaden, Germany). Simultaneously, liver tissues were homogenized in ice-cold phosphate-buffered saline (PBS) (pH 7.0). Aliquots of tissue homogenates were used to measure malondialdehyde (MDA) levels, antioxidant enzyme
activity [i.e. catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GR)] and glutathione (GSH) content following the instructions supplied with relevant assay kits (Bio-Diagnostic, Giza, Egypt). For nitric oxide (NO), the Biodiagnostic Nitrite Assay Kit was used which provides an accurate and convenient method for measurement of endogenous nitrite concentration as indicator of NO production. In addition, enzyme-linked immunosorbent assay (ELISA) kits were used to measure the hepatic levels of TNF-α and IL-6 (BioSource International Inc., Camarillo, CA, USA). The concentration of protein was determined using the method of Bradford, and crystalline bovine serum albumin was used as a standard.

**Electron microscopy of the rat liver**

Small pieces of rat liver were immediately fixed in 3% glutaraldehyde in sodium phosphate buffer (200 mM, pH 7.2) for 3 h at 4°C, followed by postfixation in 1% osmium tetroxide (cold) for 1 h. The tissue samples were dehydrated in graded ethanol solutions and embedded in Araldite. Next, blocks were trimmed and sectioned with a Leica EM UC6 ultramicrotome. Ultrathin sections (80–100 nm) were mounted on 200 mesh Cu grids, double stained with 4% uranyl acetate (15 min) and 1% lead citrate (2 min). Stained sections were examined under a transmission electron microscope (Jeol JEM 1011) at 80 kV.

**Cell culture**

Low-passage HepG2 cells were cultured in Dulbecco’s modified Eagle’s minimum essential medium (DMEM, Gibco), supplemented with 10% heat-inactivated fetal bovine serum (FBS), 50 IU/ml penicillin/streptomycin (Lonza Co., Belgium) at 37°C in a 5% CO₂ atmosphere. Cells were routinely subcultured and washed with phosphate-buffered saline (PBS). Cells were treated at 70-80% confluency.

**Cell viability assay (MTT assay)**

HepG2 cells were cultured as described above. A total of \(5 \times 10^4\) cells/well were seeded in a 96-well plate and allowed to attach and grow to optimal densities. Cells were
treated with increasing concentrations of MTX and/or Nar. Controls were performed in which cells were treated with 0.1-1% DMSO. After 48 h of incubation, the cells were washed twice with PBS. Then, 10 µl of 12 mM MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added to each well prior to further incubation at 37°C for 4 h. The reaction was stopped after adding 100 µl of DMSO to each well. The experiment was performed in triplicate in parallel for each concentration. The mixture was shaken on a microvibrator for 5 min, and the absorbance was read at 570 nm (A) using a microplate ELISA reader. The viability percentage (V %) was calculated using the following equation: V % = [(A_{treated} – A_{blank})/A_{control} – A_{blank}] × 100. A semilogarithmic plot of the cell viability percentage of HepG2 cells versus increasing concentrations of MTX and/or Nar was employed to calculate the absolute IC_{50} (GI_{50}) which is the concentration corresponding to 50% inhibition of the viability of HepG2 cells.

**In vitro morphological analysis**

HepG2 cells were subjected to the absolute IC_{50} of MTX and/or Nar for 48 h at 37°C in 5% CO_{2}. Experiments included controls exposed to 0.1-1% DMSO. After the incubation period, the cells were washed with PBS, fixed with 10% buffered formalin, examined and photographed using an inverted phase contrast microscope (Optika, Italy) at ×400 magnification.

**Western blotting analysis**

Treated and untreated cancer cells were lysed in a 1% NP-40-containing buffer supplemented with a 1 × cocktail of protease inhibitors (Roche, Germany) and phosphatase inhibitors (Sigma-Aldrich, USA) at 4°C for 30 min. Lysates were centrifuged at 10,000 xg at 4°C for 15 min, and the supernatants were collected. Protein concentrations were determined using the BCA Protein Assay Kit (Pierce, Rockford, IL). Samples were mixed at a ratio of 1:2 in Laemmli buffer and denatured by heating at 98°C for 5 min. A total of 40 µg of total protein was separated on 10% Tris-SDS-PAGE gels at 100 V for 1 h. For western blotting, the separated proteins were electrophoretically blotted onto a prewetted nitrocellulose membrane (BioRad Laboratories, USA) in Tris-buffered saline with Tween-20 (TBST; 20 mM Tris-HCl, pH 7.6, 137 mM NaCl) at 70 V
for 2 h. Membranes were blocked for 30 min in blocking buffer (5% nonfat dry milk) followed by washing in TBST. Blotted proteins were probed with specific primary antibodies (Santa Cruz Biotechnology, USA) overnight at 4°C prior to incubation for 1 h in the appropriate horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, USA). β-Actin (Sigma-Aldrich, USA) was used as a loading control. An ECL kit was used for detection according to the manufacturer’s instructions (Amersham, UK). Densitometry quantification of protein bands was carried out using Quantity One software (BioRad Laboratories, USA).

**Statistical analysis**

Data were expressed as the mean ± standard error (SE), and the differences among groups were evaluated by one-way analysis of variance (ANOVA) followed by Tukey’s test. In all cases, differences were considered statistically significant at $p < 0.05$. All statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Prism Software Inc., San Diego, CA, USA).

**Results**

**Nar alleviates MTX-induced liver dysfunction in rats**

The levels of serum ALT, AST, ALP and total bilirubin in the MTX group were significantly increased compared to those in the control group (Table 1). However, in the MTX + Nar groups, the abovementioned parameters significantly decreased compared to those of the MTX group. Indeed, the highest dose of Nar (80 mg/kg) markedly normalized the excessive levels of serum ALT, ALP and bilirubin induced by MTX.

**Nar ameliorates MTX-induced hepatic oxidative stress in rats**

The results of the oxidant status of the liver tissue are presented in Table 2. We found a significant reduction in SOD, CAT, GPX, GR and GSH in rats treated with MTX. Nar administration inhibited the decrease in enzymatic activities and GSH levels in a dose-dependent manner compared to the MTX administration. Interestingly, Nar at 80 mg/kg restored CAT activity to normal levels. It was also evident that treatment with MTX
significantly increased MDA and NO levels when compared to the “no treatment” control. However, MDA and NO levels were much lower in the MTX+Nar group than in the MTX group.

Nar ameliorates MTX-induced proinflammatory cytokines in the rat liver
As shown in Table 3, the MTX-treated rats exhibited a significant increase in the levels of hepatic TNF-α and IL-6 compared to the control rats. In contrast, Nar treatments induced a significant decrease in the levels of these cytokines compared to MTX treatment. In particular, the highest tested dose of Nar was more effective than the two lower doses in reducing the elevated levels of IL-6 and TNF-α following MTX treatment.

Nar improves MTX-induced hepatocyte ultrastructural changes in rats
Electron microscopic examination of liver sections of control rats displayed normal architecture (Fig. 1a). The cytoplasm of hepatocytes contained abundant mitochondria with well-developed cristae. The rough endoplasmic reticulum (RER) consisted of closely packed parallel and flattened cisternae. The nuclei appeared spherical with a small amount of heterochromatin at the peripheral regions and a large central amount of euchromatin. In the MTX group, RER cisternae of hepatocytes were fragmented, and mitochondria were reduced and had ill-defined cristae, karyolysis was prominent, normal structure was almost absent, and extensive fat droplets could be seen (Fig. 1b). Treatment with Nar rescued the morphology of the hepatocytes and restored the cytoplasmic organelles, more strongly with increasing dosage. Although slight degeneration was observed in the cytoplasm of liver cells treated with low and medium doses of Nar, less fragmented RER was observed, and mitochondria were well-protected (Fig. 1c-d). The high dose of Nar significantly prevented ultrastructural damage to the hepatocytes (Fig. 1e).

Nar enhances the cytotoxicity of MTX against HepG2 cells
To investigate the effect of MTX and/or Nar on the growth inhibition of HepG2 cells, an MTT assay was employed. Compared with the respective untreated control cells, cells
treated with increasing concentrations of MTX and/or Nar (12.5 μM - 3.2 mM) for 48 h exhibited decreased cell viability. As indicated in Figure 2a, compared to control cells, the significant decline in the viability of MTX- and/or Nar-treated HepG2 cells started after the treatment with the lowest doses of MTX and/or Nar ($p < 0.01$) and was significantly dose-dependent. MTX treatments exhibited more efficient inhibition (absolute $IC_{50} = 0.8$ mM) viability than Nar treatments (absolute $IC_{50} = 2$ mM). Noticeably, the inhibition of the viability of HepG2 cells was significantly improved after cotreatment with MTX and Nar (absolute $IC_{50} = 0.3$ mM for both) (Fig. 2b).

**MTX and/or Nar induce morphological alterations in HepG2 cells**

We evaluated the effect of MTX and/or Nar treatment on HepG2 cell morphology after a 48 h treatment period. The untreated cells showed a high confluency rate and normal monolayer formation compared to treated cells. The morphological changes of treated cells are shown in Figure 3. Morphological alterations and decreases in HepG2 cell dimensions and density were observed in treated cells when compared to control cells. Treated cells exhibited a disturbed monolayer, swelling and rounded morphology with condensed chromatin; cells became shrunken, rounded in shape, showing blebbing and an increased number of floating cells, while untreated cells had an intact appearance.

**Nar potentiates the MTX effect on the Bax/Bcl-2 ratio in HepG2 cells**

To further investigate the effect of MTX and/or Nar on HepG2 cells, the expression levels of the proapoptotic protein Bax and the antiapoptotic protein Bcl-2, which are involved in proliferation, were evaluated. HepG2 cells were treated with the absolute $IC_{50}$ of Nar and/or MTX for 48 h. The general profile of cells after different treatments, increased Bax/Bcl-2 ratio, was similar when compared to control untreated cells. Noticeably, the Bax/Bcl-2 ratio was significantly increased after cotreatment with MTX and Nar (Fig. 4).
Discussion

In this study, MTX-induced hepatotoxicity was manifested by a significant increase in the levels of serum ALT, AST and ALP enzymes. These enzymes are specific indicators of increased membrane permeability and/or necrotic damage in hepatocytes. In addition, MTX induced a concomitant increase in total bilirubin levels, which is also a clear marker of hepatic dysfunction. Liver injury was also confirmed by ultrastructural deformations in hepatocytes in the form of lipid infiltration, pyknotic or karyolysed nuclei, mitochondrial cristolysis and RER fragmentation. These changes are consistent with previous studies. Treatment of the MTX-administered rats with Nar significantly ameliorated all circulating liver function markers. In addition, Nar markedly protected cellular membranes and organelles with increasing doses, to the point that normal hepatocyte ultrastructure returned. Similar findings have been reported by Lv et al., who showed that Nar supplementation led to the resumption of elevated serum hepatic enzyme activities in perfluorooctane sulfonate-challenged mice. Another study by Zhou et al. reported that Nar reduced alcoholic hepatic steatosis, and the inhibitory effect was dose-dependent.

MTX can initiate hepatocellular oxidative damage through the excessive generation of ROS, mitochondrial dysfunction and deregulation of enzymatic or nonenzymatic antioxidant machinery. It has been reported that cytosolic NADP+-dependent dehydrogenases and NADP+-malic enzymes are inhibited by MTX, suggesting that the drug could decrease the availability of intracellular NADPH in cells, leading to depletion of cellular GSH and making cells more vulnerable to damage by ROS. ROS generation may lead to LPO and damage to cellular macromolecules, such as DNA, proteins, and lipid bilayers. Under the current experimental conditions, MTX administration induced a significant increase in LPO products (i.e., MDA) and a significant decrease in endogenous antioxidants, including GSH, CAT, SOD, GPx, and GR. This increase in redox imbalance was ameliorated by Nar treatment in a dose-dependent manner, possibly by its direct ability to scavenge free radicals, or through the transcriptional upregulation of antioxidant genes. These results are consistent with reports of other investigators. Several studies have reported that the antioxidant and anti-inflammatory effects of Nar are retained up to 400 mg/kg exposure.
addition, Nar have a high safety margin towards cultured primary rat hepatocytes (IC50 = 99.6 g/ml). 44

MTX administration has been shown to produce a significant increase in the levels of proinflammatory cytokines, such as TNF-α and IL-6, as well as NO production. 44,45 Excess NO in the presence of superoxide anions may generate peroxynitrite radicals, cytotoxic prooxidants that causes protein nitration and cellular damage. 46 In addition, excess NO depletes intracellular GSH levels, thus increasing the susceptibility to oxidative stress. 47 The results of the present study revealed that the increase in TNF-α, IL-6 and NO levels was inhibited by Nar treatment when supplemented prior to and after MTX administration. This finding is consistent with previous studies. 48,49

iNOS is not constantly present in cells and accumulating evidences point out the involvement of iNOS in the production of NO when the cell is induced or stimulated, typically by proinflammatory cytokines and/or bacterial lipopolysaccharide. Upon induction, iNOS generates significant amounts of NO (micromolar range), which lasts sometimes for hours. Constitutive NOS (cNOS), by contrast, generate and release NO mainly in resting cells and produce nanomolar amounts of NO for short periods of time. 50,51 Different experimental works have shown that cNOS activity is markedly inhibited by NO itself, whereas iNOS activity is highly resistant to inhibition by NO. 52 It is well established that pro-inflammatory cytokines are potent inducers of iNOS in a wide variety of cells types, with consequent production of NO. 53 The gene expression of iNOS and the subsequent mRNA translation are regulated by various stimuli, especially endogenous proinflammatory mediators such as TNF-α, IL-1β, IL-6, and IFN-γ. Hence, the expression of iNOS can only be induced by inflammatory stimuli and contribute to the large amount of NO production. 50 The mechanism for the Nar anti-inflammatory action might involve the inhibition of NF-κB and iNOS signaling pathway. 31,37

Regardless of the combined efforts of governments and researchers globally, there has been a continuous rise in the incidence rate of hepatocellular carcinoma (HCC) during the last two decades. 54 Towards the second aim of this study, HepG2 cells, as a model for HCC, were used to investigate the possible cytotoxic and antiproliferative effects of MTX and/or Nar. MTX and/or Nar provoked evident antitumor activity in
HepG2 cells, as assessed by *in vitro* cytotoxicity, morphological alterations, and the Bax/Bcl-2 protein expression ratio, which is consistent with what has been reported previously *in vitro* and *in vivo*. The reduction in the percentage of cell viability was dose-dependent following 48 h of treatment. The MTT results showed that MTX and/or Nar significantly inhibited the proliferation of HepG2 cells. Cells were more sensitive to MTX and Nar cotreatment (absolute IC\textsubscript{50} = 0.3 mM for each) than either MTX (absolute IC\textsubscript{50} = 0.8 mM) or Nar (absolute IC\textsubscript{50} = 2 mM) treatment alone. The treatment with MTX alone resulted in a non-typical growth inhibitory action on cancer cells with two concentration areas of inhibitory action: one below 10 µM and other above 1 mM. This most probably indicates two different inhibition mechanisms and/or two different targets. In case of the combined treatment of MTX+Nar, the inhibitory effect below 10 µM may be related to the action of MTX alone, whereas the inhibition around 1 mM may be caused by the combined action of both compounds. We did not investigate the effect of concentrations below 10 µM.

The induction of apoptosis is an important pathophysiological strategy through which an ideal antitumor agent acts to arrest cancer cell growth. Apoptosis is typically characterized by morphological alterations. Morphological examination of treated cells revealed apoptotic HepG2 cells with obvious changes in morphology, including cell shrinkage and nuclear chromatin condensation, implying the involvement of MTX and/or Nar, as reported previously.

Although the antiproliferative effect of Nar on HepG2 cells has been reported, the molecular mechanism involved remains unclear. Here, the immunoblotting analysis showed an upregulation of the proapoptotic Bax and downregulation of the antiapoptotic Bcl-2 upon treatment with MTX and/or Nar. The induction of apoptosis is a protective mechanism to eliminate neoplastic cells. Apoptosis may be initiated via the activation of the extrinsic or intrinsic pathways or both. Mitochondria are involved in the intrinsic apoptosis pathway. This apoptotic pathway is regulated by Bax, Bcl-2 and cytochrome c and eventually leads to the activation of caspase-3 and poly (ADP-ribose) polymerase (PARP). The activation of caspases is regulated by the fine balance of the ratios of Bax and Bcl-2 proteins, a mechanism that regulates the survival/apoptosis decision of a cell. The observed altered expression of Bax and Bcl-2 upon MTX and/or Nar treatment
of HepG2 cells in a manner that favors the increase in the Bax/Bcl-2 ratio could underlie the observed apoptotic effect and has been reported previously. The oligomerization of Bax on the outer mitochondrial membrane, as a result of excessive oxidative stress, leads to cytochrome c-release and degradation of Bcl-2. Here, while exposure to either MTX or Nar increased the Bax/Bcl-2 protein expression ratio, the combination of both treatments induced a more pronounced increase in the Bax/Bcl-2 ratio. This finding implies that the cotreatment of MTX and Nar synergistically aggraviated their apoptotic effect in HepG2 cells. Many studies have reported that the deregulation of apoptosis-related proteins with a mechanism of action comparable to that of Nar, which further supports its role in apoptosis induction.

Nar can have a cytoprotective or apoptotic effect. Many studies have reported the apoptotic effect of Nar in different human cancer cell lines via various mechanisms and signaling pathways. Nar induces apoptosis in HeLa and HepG2 cells through activation of caspase-3, increased Bax/Bcl-2 ratio, and upregulation of miR-19b expression; in cervical cancer SiHa cells via death receptor and mitochondrial pathways; and in gastric adenocarcinoma AGS cells via autophagic cell death through downregulation of the PI3K/Akt/mTOR pathway, upregulation of p21, activation of Beclin 1 and LC3B, and phosphorylation MAPK.

**Conclusion**

In summary, the results of this experiment suggest that Nar can reverse MTX-induced hepatic damage through reduction of MDA, NO, TNF-α, and IL-6 with the abrogation of cellular antioxidant defenses. Moreover, Nar potentiates the cytotoxic and anti-viability effect of MTX on HepG2 cancer cells. *In vivo* experiments using tumor-bearing animal models are required to determine if MTX and/or Nar are efficacious and safe for use as anticancer drugs.
Acknowledgments

The authors would like to thank the Deanship of Scientific Research at King Faisal University (Saudi Arabia) for financial support and providing grant funding to conduct this study (project no. 170046).

Authors’ contributions

HE, MK and AMA designed the experiments. HE and MK performed the biochemical and cell biological experiments. HE, AIA, MA, AS, OME and AMA performed the animal experiments. MA, AS, OME and AMA performed the electron microscopy investigations. All authors contributed toward data analysis, drafting and critically revising the paper, and approved the final version of the manuscript.

Declaration of conflicting interests

The authors declare that they have no conflicts of interest.

References

1. Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, et al. Chemotherapy for bladder cancer: Treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. *Urology*. 2007;69:62-79.
2. Lukenbill J, Advani AS. The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia. *Curr Hematol Malig R*. 2013;8(2):91-7.
3. Bordbar M, Shakibazad N, Fattahi M, Haghpanah S, Honar N. Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia. *Turk J Gastroenterol*. 2018;29(2):203-9.
4. Abo-Haded HM, Elkablawy MA, Al-Johani Z, Al-ahmadi O, El-Agamy DS. Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity. *Plos One*. 2017;12(3):e0174295.
5. Hafez HM, Ibrahim MA, Ibrahim SA, Amin EE, Goma W, Abdelrahman AM. Potential protective effect of etanercept and aminoguanidine in methotrexate-induced hepatotoxicity and nephrotoxicity in rats. *Eur J Pharmacol*. 2015;768:1-12.
6. Liedtke C, Trautwein C. The role of TNF and Fas dependent signaling in animal models of inflammatory liver injury and liver cancer. *Eur J Cell Biol*. 2012;91(6-7):582-9.

7. Rao P, Hayden MS, Long MX, Scott ML, West AP, Zhang DK, et al. I kappa B beta acts to inhibit and activate gene expression during the inflammatory response. *Nature*. 2010;466(7310):1115-132.

8. Cetiner M, Sener G, Sehirli AO, Eksioglu-Demiralp E, Ercan F, Sirvanci S, et al. Taurine protects against methotrexate-induced toxicity and inhibits leukocyte death. *Toxicol Appl Pharm*. 2005;209(1):39-50.

9. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. *Blood*. 2012;119(3):651-65.

10. Leitao RFC, Brito GAC, Oria RB, Braga-Neto MB, Bellaguarda EAL, Silva JV, et al. Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents. *BMC gastroenterology*. 2011;11:90.

11. Gupta RK, Patel AK, Shah N, Choudhary AK, Jha UK, Yadav UC, et al. Oxidative Stress and Antioxidants in Disease and Cancer: A Review. *Asian Pac J Cancer Prev*. 2014;15(11):4405-9.

12. Lee MH, Yoon S, Moon JO. The flavonoid naringenin inhibits dimethylnitrosamine-induced liver damage in rats. *Biol Pharm Bull*. 2004;27(1):72-6.

13. Erdogan S, Doganlar O, Doganlar ZB, Turkekul K. Naringin sensitizes human prostate cancer cells to paclitaxel therapy. *Prostate Int*. 2018;6(4):126-35.

14. Mahmoud AM, Ashour MB, Abdel-Moneim A, Ahmed OM. Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fatfed/streptozotocin-induced type 2 diabetic rats. *J Diabetes Complicat*. 2012;26(6):483-90.

15. El-Desoky AH, Abdel-Rahman RF, Ahmed OK, El-Beltagi HS, Hattori M. Anti-inflammatory and antioxidant activities of naringin isolated from Carissa carandas L.: *In vitro and in vivo* evidence. *Phytother Res*. 2018;42:126-34.

16. Liang J, Wang CY, Peng JY, Li WS, Jin Y, Liu Q, et al. Naringin regulates cholesterol homeostasis and inhibits inflammation via modulating NF-kappa B and ERK signaling pathways *in vitro*. *Pharmazie*. 2016;71(2):101-8.

17. Banjerdpongchai R, Wudtiwai B, Khawon P. Induction of Human Hepatocellular Carcinoma HepG2 Cell Apoptosis by Naringin. *Asian Pac J Cancer Prev*. 2016;17(7):3289-94.

18. Xie DF, Yuan PW, Wang D, Jin H, Chen H. Effects of naringin on the expression of miR-19b and cell apoptosis in human hepatocellular carcinoma. *Oncol Lett*. 2017;14(2):1455-9.
21. Shen W, Xu Y, Lu YH. Inhibitory Effects of Citrus Flavonoids on Starch Digestion and Antihyperglycemic Effects in HepG2 Cells. J Agr Food Chem. 2012;60(38):9609-19.

22. Zhang JK, Sun CD, Yan YY, Chen QJ, Luo FL, Zhu XY, et al. Purification of naringin and neohesperidin from Huyou (Citrus changshaniensis) fruit and their effects on glucose consumption in human HepG2 cells. Food Chem. 2012;135(3):1471-8.

23. Mohamed EA, Abu Hashim II, Yusif RM, Shaaban AAA, EI-Sheakh AR, Hamed MF, et al. Polymeric micelles for potentiated antiulcer and anticancer activities of naringin. Int J Nanomed. 2018;13:1009-27.

24. Golechha M, Sarangal V, Bhatia J, Chaudhry U, Saluja D, Arya DS. Naringin ameliorates pentoxifylline and alpha lipoic acid on methotrexate-induced damage in liver and kidney of rats. Environ Toxicol Phar. 2015;39(3):1122-31.

25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.

26. Al-Ali SY, Hassan IM, Sadek S. Ultrastructural changes in rat livers perfused in vitro and in vivo with a high dose of methotrexate. Histol Histopathol. 2005;20(4):1131-45.
Damage: Alleviation by N-Acetylcyesteine and N-Acetylcysteine Amide. *Plos One.* 2015;10(6):e0127558.

36. Moskovitz J, Yim MB, Chock PB. Free radicals and disease. *Arch Biochem Biophys.* 2002;397(2):354-9.

37. Chtourou Y, Aouey B, Kebieche M, Fetoui H. Protective role of naringin against cisplatin induced oxidative stress, inflammatory response and apoptosis in rat striatum via suppressing ROS-mediated NF-κB and P53 signaling pathways. *Chem-Biol Interact.* 2015;239:76-86.

38. Jeon SM, Bok SH, Jang MK, Lee MK, Nam KT, Park YB, et al. Antioxidative activity of naringin and lovastatin in high cholesterol-fed rabbits. *Life Sci.* 2001;69(24):2855-66.

39. Adil M, Kandhare AD, Ghosh P, Bodhankar SL. Sodium arsenite-induced myocardial bruise in rats: Ameliorative effect of naringin via TGF-beta/Smad and Nrf/HO pathways. *Chem-Biol Interact.* 2016;253:66-77.

40. Nzuza S, Owira P. Naringin abrogates HIV-1 protease inhibitors-induced atherogenic dyslipidemia and oxidative stress *in vivo.* *J Funct Foods.* 2019;52:156-164.

41. Jung UJ, Kim HJ, Lee JS, Park EJ, et al. Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects. *Clin Nutr.* 2003;22(6), 561-8.

42. Jagetia GC, Reddy TK, Venkatesha VA, Kedlaya R. Influence of naringin on ferric iron induced oxidative damage *in vitro.* *Clin Chim Acta.* 2004;347(1-2):189-97.

43. Singh D, Chopra K. The effect of naringin, a bioflavonoid on ischemia-reperfusion induced renal injury in rats. *Pharmacol Res.* 2004;50:187-93.

44. El-Desoky AH, Abdel-Rahman RF, Ahmed OK, El-Beltagi HS, Hattori M. Anti-inflammatory and antioxidant activities of naringin isolated from *Carissa carandas* L.: *In vitro* and *in vivo* evidence. *Phytomedicine.* 2018;42,126-34.

45. Abdel-Daim MM, Khalifa HA, Abushouk AI, Dkhil MA, Al-Quraishy SA. Diosmin Attenuates Methotrexate-Induced Hepatic, Renal, and Cardiac Injury: A Biochemical and Histopathological Study in Mice. *Oxid Med Cell Longev.* 2017;2017:3281670.

46. Groeneveld PHP, Kwappenberg KMC, Langermans JAM, Nibbering PH, Curtis L. Nitric oxide (NO) production correlates with renal insufficiency and multiple organ dysfunction syndrome in severe sepsis. *Intensive Care Med.* 1996;22(11):1197-202.

47. Jung M, Hotter G, Viñas JL, Sola A. Cisplatin upregulates mitochondrial nitric oxide synthase and peroxynitrite formation to promote renal injury. *Toxicol Appl Pharm.* 2009;234(2):236-46.

48. Xianchu L, Lan PZ, Quifang L, Yi L, Xiangcheng R, Wenqi H, et al. Naringin protects against lipopolysaccharide-induced cardiac injury in mice. *Environ Toxicol Phar.* 2016;48:1-6.

49. Gelen V, Şengül E, Yıldırım S, Atila G. The protective effects of naringin against 5-fluorouracil-induced hepatotoxicity and nephrotoxicity in rats. *Iran J Basic Med Sci.* 2018;21(4):404-10.

50. Yu X, Ge L, Niu L, Lian X, Ma H, Pang L. The dual role of inducible nitric oxide synthase in myocardial ischemia/reperfusion injury: friend or foe? Oxidative medicine and cellular longevity. 2018: Article ID 8364848:7 pages.
51. Cinelli MA, Do HT, Miley GP, Silverman RB. Inducible nitric oxide synthase: Regulation, structure, and inhibition. Medicinal research reviews. 2020;40(1):158-89.

52. Cernadas MR, de Miguel LS, García-Durán M, González-Fernández F, Millás I, Montón M, Rodrigo J, Rico L, Fernández P, de Frutos T, Rodríguez-Feo JA. Expression of constitutive and inducible nitric oxide synthases in the vascular wall of young and aging rats. Circulation Research. 1998;83(3):279-86.

53. Leitão RF, Brito GA, Oriá RB, Braga-Neto MB, Bellaguarda EA, Silva JV, Gomes AS, Lima-Júnior RC, Siqueira FJ, Freire RS, Vale ML. Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents. BMC gastroenterology. 2011;11(1):90.

54. Alwhibi MS, Khalil MIM, Ibrahim MM, El-Gaaly GA, Sultan AS. Potential Antitumor Activity and Apoptosis Induction of Glossostemon bruguieri Root Extract against Hepatocellular Carcinoma Cells. Evid-Based Compl Alt. 2017;2017:7218562.

55. Bonavida B, Garban H. Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemoinmunotherapeutics. Redox Biol. 2015;6:486-94.

56. Sultan AS, Khalil MIM, Sami BM, Alkhuriji AF, Sadek O. Quercetin induces apoptosis in triple-negative breast cancer cells via inhibiting fatty acid synthase and beta-catenin. Int J Clin Exp Patho. 2017;10(1):156-72.

57. Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol. 2013;25(1):50-1.

58. Zhu L, Han MB, Gao Y, Wang H, Dai L, Wen Y, et al. Curcumin triggers apoptosis via upregulation of Bax/Bcl-2 ratio and caspase activation in SW872 human adipocytes. Mol Med Rep. 2015;12(1):1151-6.

59. Liu Z, Ding Y, Ye N, Wild C, Chen H, Zhou J. Direct Activation of Bax Protein for Cancer Therapy. Med Res Rev. 2016;36(2):313-41.

60. Arumugam S, Girish Subbiah K, Kemparaju K, Thirunavukkarasu C. Neutrophil extracellular traps in acrolein promoted hepatic ischemia reperfusion injury: Therapeutic potential of NOX2 and p38MAPK inhibitors. J Cell Physiol. 2018;233(4):3244-61.

61. Chen YJ, Wu CL, Liu JF, Fong YC, Hsu SF, Li TM, et al. Honokiol induces cell apoptosis in human chondrosarcoma cells through mitochondrial dysfunction and endoplasmic reticulum stress. Cancer Lett. 2010;291(1):20-30.

62. Arul D, Subramanian P. Naringenin (Citrus Flavonone) Induces Growth Inhibition, Cell Cycle Arrest and Apoptosis in Human Hepatocellular Carcinoma Cells. Pathol Oncol Res. 2013;19(4):763-70.

63. Zeng L, Zhen Y, Chen Y, Zou L, Zhang Y, Hu F, et al. Naringin inhibits growth and induces apoptosis by a mechanism dependent on reduced activation of NFkappaB/COX2caspase-1 pathway in HeLa cervical cancer cells. Int J Oncol. 2014;45(5):1929-36.

64. Ramesh E, Alishatwi AA. Naringin induces death receptor and mitochondria-mediated apoptosis in human cervical cancer (SiHa) cells. Food Chem Toxicol. 2013;51:97-105.

65. Raha S, Yumnam S, Hong GE, Lee HJ, Saralamma VV, Park HS, et al. Naringin induces autophagy-mediated growth inhibition by downregulating the
PI3K/Akt/mTOR cascade via activation of MAPK pathways in AGS cancer cells. *Int J Oncol.* 2015;47(3):1061-9.

**Legends of figures:**

**Figure 1:** Representative transmission electron micrographs of rat hepatocytes. (a) Control, (b) MTX, (c) MTX+Nar20, (d) MTX+Nar40, and (e) MTX+Nar80. N = Nucleus, M = Mitochondria, RER = Rough Endoplasmic Reticulum, and L = Lipid droplet.

**Figure 2:** Nar enhanced the cytotoxicity of MTX against HepG2 cells. Cells were treated with increasing concentrations of Nar and/or MTX (12.5 μM - 3.2 mM) for 48 h. Controls were treated with DMSO only. (a) The effects of MTX and/or Nar on the proliferation of HepG2 cells are expressed as a percentage of cell viability; (b) A semilogarithmic plot of the cell viability percentage of HepG2 cells over the 48 h exposure to increasing concentrations of MTX and/or Nar. IC\textsubscript{50}; absolute IC\textsubscript{50} is the concentration that corresponds to 50% inhibition of the viability of HepG2 cells. Data from at least three independent experiments performed in at least triplicate are presented as the means ± SEM, *p < 0.01 vs. control group.

**Figure 3:** MTX- and/or Nar-induced morphological alterations in HepG2 cells. Cells were plated in 12-well plates and treated with the absolute IC\textsubscript{50} of MTX and/or Nar for 48 h. The photographs were taken from culture plates using a phase contrast microscope at × 400 magnification. Control cells were treated with DMSO only. Representative pictures are shown from three independent experiments.

**Figure 4:** Bax and Bcl-2 expression levels and Bax/Bcl-2 ratio in MTX and/or Nar-treated HepG2 cells. Cells were plated in 6-well plates and treated with the absolute IC\textsubscript{50} of MTX and/or Nar for 48 h. (a) Expression levels of Bax and Bcl-2 in HepG2 cells; (b) Bax/Bcl-2 ratio in HepG2 cells. Data from at least three independent experiments are presented as the means ± SE, *Significant difference with control (**p < 0.01). §Significant difference with the MTX group (\^p < 0.01). $Significant difference with the Nar group ($p < 0.05).
Naringin alleviates methotrexate-induced liver injury in male albino rats and enhances its antitumor efficacy in HepG2 cells

Hany Elsawy¹,², Abdulmohsen I. Algefare³, Manal Alfwuaires³, Mahmoud Khalil⁴,⁵, Omar M. Elmenshawy⁶, Azza Sedky³,⁵, Ashraf M. Abdel-Moneim³,⁵,*

¹Department of Chemistry, Faculty of Science, King Faisal University, Al-Ahsa, Saudi Arabia
²Department of Chemistry, Faculty of Science, Tanta University, Tanta, Egypt
³Department of Biological Sciences, Faculty of Science, King Faisal University, Hofuf-31982, Al-Ahsa, Saudi Arabia.
⁴Department of Biological Sciences, Faculty of Science, Beirut Arab University, Lebanon
⁵Department of Zoology, Faculty of Science, Alexandria University, Alexandria, Egypt
⁶Department of Zoology, Faculty of Science, Al-Azhar University, Cairo, Egypt

*Corresponding Author:
Ashraf M. Abdel-Moneim

Department of Biological Sciences, Faculty of Science, King Faisal University, Hofuf-31982, Al-Ahsa, Saudi Arabia; Department of Zoology, Faculty of Science, Alexandria University, Alexandria, Egypt

Email:
aabdelmoneim@kfuf.edu.sa; ashraf.abdelmoneim@alexu.edu.eg

Orcid: https://orcid.org/0000-0002-0270-703X
Abstract:
Methotrexate (MTX) is an efficient chemotherapeutic and immunosuppressant drug, but the hepatotoxicity of MTX limits its clinical use. Naringin (Nar) is a flavonoid derived from Citrus paradisi, and has been shown to possess several pharmacological activities, including free-radical scavenging and antioxidant properties. In this study, we first tested the possible protective effects of multiple doses of Nar against MTX-induced acute hepatotoxicity in rats, and then we investigated the growth inhibition and apoptotic effects of MTX and/or Nar against the HepG2 hepatocarcinoma cell line. Our in vivo results showed that Nar significantly reduced MTX-induced increases in serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and total bilirubin levels. Nar also reduced MTX-induced oxidative stress by significantly reducing liver malondialdehyde and nitric oxide content and increasing superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione. In addition, Nar significantly counteracted MTX-induced increases in hepatic interleukin-6 and tumor necrosis factor-alpha. Further, Nar greatly protected hepatocyte ultrastructure against MTX-induced injury. In contrast, in vitro MTX and/or Nar treatment of HepG2 cells for 48 h exhibited a cytotoxic effect and induced apoptosis in a dose-dependent manner mediated by a significant increase in the Bax/Bcl-2 protein expression ratio. Noticeably, Nar potentiated the MTX effect on the Bax/Bcl-2 ratio. In conclusion, Nar decreased MTX-induced functional and ultrastructural liver damage in a tumor-free animal model. Also, our data introduce MTX and Nar as promising antiproliferative agents with a distinctive mode of action, inducing apoptosis in HepG2 tumor cells through activation of Bax and downregulation of Bcl-2 protein expression.

Keywords: Naringin, methotrexate, liver oxidative damage, HepG2 cells, Bax/Bcl-2 ratio
Introduction

Methotrexate (MTX), a folic acid antagonist, is widely used in the treatment and prophylaxis of several types of malignant tumors.¹ ² However, MTX is known to induce liver damage in animals, and more than 10% of patients receiving MTX.³ Several studies have shown that MTX toxicity is mediated by oxidative stress and dysregulation of antioxidant defenses, thereby increasing the generation of reactive oxygen species (ROS) as superoxide anions, hydrogen peroxide and hydroxyl radicals.⁴ ROS formation can initiate lipid peroxidation (LPO) and the release of inflammatory mediators, including tumor necrosis factor-alpha (TNF-α) and inducible nitric oxide synthase (iNOS).⁵ TNF-α is a key factor in liver and kidney homeostasis. TNF-α activates proapoptotic (mainly caspases) and antiapoptotic (mainly NF-κB pathways).⁶ ⁷ Increased expression of TNF-α has been reported in a model of MTX-induced hepatic, renal and intestinal damage.⁸ The proinflammatory effect of TNF-α is mediated through NF-κB-regulated proteins, such as iNOS and cyclooxygenase-2.⁹ Nitric oxide (NO) is a free radical molecule with a multitude of physiological functions. This highly reactive molecule is synthesized from L-arginine by a group of isoenzymes collectively termed NO synthases (NOS). The role of iNOS has been implicated in the pathogenesis of MTX-induced toxicity.¹⁰ Therefore, attenuation of oxidative stress can represent an effective strategy to protect against MTX-induced hepatotoxicity.

Recently, several reports have highlighted the role of antioxidants in preventing diseases through free radical scavenging mechanisms.¹¹ Naringin (4',5,7-trihydroxyflavanone-7-rhamnoglucoside) (Nar) is a bioflavonoid and polyphenolic compound that is found in grapefruit, orange and cooked tomato paste and is associated with citrus herb species.¹²
Studies have shown that Nar has a broad spectrum of biological and pharmacological activities, including hepatoprotective, anticarcinogenic, antidiabetic, and anti-inflammatory effects.

According to the latest world cancer statistics published by the International Agency for Research on Cancer (IARC)-Global Cancer Observatory (GCO) (Globocan 2018), liver cancer is ranked fourth on the list of cancer-related deaths. Based on IARC statistics, the estimated number of deaths from liver cancer in 2018 is approximately 0.8 million deaths, and the mortality burden projections worldwide will be increased by 66% in 2040. Few reports have highlighted the effects of Nar in HepG2 cells, including restraining inflammatory markers such as c-reactive protein and TNF-α, quenching NF-κB and ERK1/2 activities, and inducing apoptosis via the mitochondrial pathway, and via the upregulation of miR-19b and Bax/Bcl-2 protein ratio expression. In addition, it has been reported that the antihyperglycemic effects of Nar in HepG2 cells are associated with the upregulation of phospho-AMP-activated protein kinase (pAMPK), a key enzyme in the regulation of cellular energy homeostasis. In a very recent study, the polymeric micellization of Nar with pluronic F-68, a nonionic surfactant, was shown to enhance the antitumor activity of Nar against HepG2, MCF-7, and Caco-2 cells. Furthermore, Nar–PF68 micelles inhibit tumor growth in Ehrlich ascites carcinoma-bearing mice. To the best of our knowledge, the dual effect of Nar and MTX on hepatocellular carcinoma has not been investigated. Considering the abovementioned data, first, we aimed to evaluate the protective potential of Nar on MTX-induced hepatotoxicity in a rat model. Second, we aimed to uncover the effect of the cotreatment of Nar and MTX on the HepG2 hepatocellular carcinoma cell line.
Material and methods

Animals and treatments

The animal work was conducted at King Faisal University (Al-Ahsa, Saudi Arabia).
Animal care and experimental procedures were approved and licensed by the research ethics committee at King Faisal University (reference number: KFU-REC/2019-03-05).

Male albino rats were obtained from an animal facility at the Faculty of Science, King Saud University, Saudi Arabia. Rats (220±30 g) were housed in stainless steel wire-bottomed cages and placed in a well-ventilated animal house, maintained for two weeks for to acclimatize with food and water *ad libitum*, and subjected to a natural 12 h light:dark cycle. Rats were divided randomly into five groups (n = 6 rats each) as follows:

- Control group: Rats received daily intraperitoneal (ip) administration of saline as a vehicle.
- MTX group: Rats received a single ip dose of MTX (20 mg/kg) on the fourth day of the experiment.
- MTX+ Nar20 group: Rats received a daily ip dose of Nar (20 mg/kg) and a single ip dose of MTX (20 mg/kg) on the fourth day of the experiment.
- MTX+ Nar40 group: Rats received a daily ip dose of Nar (40 mg/kg) and a single ip dose of MTX (20 mg/kg) on the fourth day of the experiment.
- MTX+ Nar80 group: Rats received a daily ip dose of Nar (80 mg/kg) and a single ip dose of MTX (20 mg/kg) on the fourth day of the experiment.

Nar (Cat. No. 71162) and MTX (Cat. No. M9929) have been purchased from Sigma-Aldrich, USA. The drugs were dissolved in DMSO/saline with the final concentration of 1% DMSO. The duration of the experiment was 10 days. MTX and Nar doses were selected according to previous reports.5,24,25

In vivo sample collection and biochemical assays

At the end of the experimental period, rats were anesthetized with diethyl ether and sacrificed by cervical dislocation. Blood samples were collected immediately, and sera were obtained after centrifugation at 1,000 xg for 20 min and stored at −80°C until use.

Serum levels of hepatic function markers were determined using commercial kits (Human Assay Kits, Wiesbaden, Germany). Simultaneously, liver tissues were homogenized in ice-cold phosphate-buffered saline (PBS) (pH 7.0). Aliquots of tissue homogenates were used to measure malondialdehyde (MDA) levels, antioxidant enzyme...
activity [i.e. catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GR)], and glutathione (GSH) content following the instructions supplied with relevant assay kits (Bio-Diagnostic, Giza, Egypt). For nitric oxide (NO), the Biodiagnostic Nitrite Assay Kit was used which provides an accurate and convenient method for measurement of endogenous nitrite concentration as indicator of NO production and inducible nitric oxide (iNO) levels following the instructions supplied with relevant assay kits (Bio-Diagnostic, Giza, Egypt). In addition, enzyme-linked immunosorbent assay (ELISA) kits were used to measure the hepatic levels of TNF-α and IL-6 (BioSource International Inc., Camarillo, CA, USA). The concentration of protein was determined using the method of Bradford, and crystalline bovine serum albumin was used as a standard.

Electron microscopy of the rat liver

Small pieces of rat liver were immediately fixed in 3% glutaraldehyde in sodium phosphate buffer (200 mM, pH 7.2) for 3 h at 4°C, followed by postfixation in 1% osmium tetroxide (cold) for 1 h. The tissue samples were dehydrated in graded ethanol solutions and embedded in Araldite. Next, blocks were trimmed and sectioned with a Leica EM UC6 ultramicrotome. Ultrathin sections (80–100 nm) were mounted on 200 mesh Cu grids, double stained with 4% uranyl acetate (15 min) and 1% lead citrate (2 min). Stained sections were examined under a transmission electron microscope (Jeol JEM 1011) at 80 kV.

Cell culture

Low-passage HepG2 cells were cultured in Dulbecco's modified Eagle's minimum essential medium (DMEM, Gibco), supplemented with 10% heat-inactivated fetal bovine serum (FBS), 50 IU/ml penicillin/streptomycin (Lonza Co., Belgium) at 37°C in a 5% CO₂ atmosphere. Cells were routinely subcultured and washed with phosphate-buffered saline (PBS). Cells were treated at 70-80% confluency.
Cell viability assay (MTT assay)

HepG2 cells were cultured as described above. A total of 5-10 × 10^4 cells/well were seeded in a 96-well plate and allowed to attach and grow to optimal densities. Cells were treated with increasing concentrations of MTX and/or Nar. Controls were performed in which cells were treated with 0.1-1% DMSO. After 48 h of incubation, the cells were washed twice with PBS. Then, 10 μl of 12 mM MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added to each well prior to further incubation at 37°C for 4 h. The reaction was stopped after adding 100 μl of DMSO to each well. The experiment was performed in triplicate in parallel for each concentration. The mixture was shaken on a microvibrator for 5 min, and the absorbance was read at 570 nm (A) using a microplate ELISA reader. The viability percentage (V %) was calculated using the following equation: V % = [(A_treated − A_blank)/A_control − A_blank] × 100. A semilogarithmic plot of the cell viability percentage of HepG2 cells versus increasing concentrations of MTX and/or Nar was employed to calculate the absolute IC_{50} (GI_{50}) which is the concentration corresponding to 50% inhibition of the viability of HepG2 cells.

In vitro morphological analysis

HepG2 cells were subjected to the absolute IC_{50} of MTX and/or Nar for 48 h at 37°C in 5% CO₂. Experiments included controls exposed to 0.1-1% DMSO. After the incubation period, the cells were washed with PBS, fixed with 10% buffered formalin, examined and photographed using an inverted phase contrast microscope (Optika, Italy) at ×400 magnification.

Western blotting analysis

Treated and untreated cancer cells were lysed in a 1% NP-40-containing buffer supplemented with a 1 × cocktail of protease inhibitors (Roche, Germany) and phosphatase inhibitors (Sigma-Aldrich, USA) at 4°C for 30 min. Lysates were centrifuged at 10,000 ×g at 4°C for 15 min, and the supernatants were collected. Protein concentrations were determined using the BCA Protein Assay Kit (Pierce, Rockford, IL). Samples were mixed at a ratio of 1:2 in Laemmli buffer and denatured by heating at 98°C for 5 min. A total of 40 μg of total protein was separated on 10% Tris-SDS-PAGE gels at...
100 V for 1 h. For western blotting, the separated proteins were electrophoretically blotted onto a prewetted nitrocellulose membrane (BioRad Laboratories, USA) in Tris-buffered saline with Tween-20 (TBST; 20 mM Tris-HCl, pH 7.6, 137 mM NaCl) at 70 V for 2 h. Membranes were blocked for 30 min in blocking buffer (5% nonfat dry milk) followed by washing in TBST. Blotted proteins were probed with specific primary antibodies (Santa Cruz Biotechnology, USA) overnight at 4°C prior to incubation for 1 h in the appropriate horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, USA). β-Actin (Sigma-Aldrich, USA) was used as a loading control. An ECL kit was used for detection according to the manufacturer’s instructions (Amersham, UK). Densitometry quantification of protein bands was carried out using Quantity One software (BioRad Laboratories, USA).

Statistical analysis
Data were expressed as the mean ± standard error (SE), and the differences among groups were evaluated by one-way analysis of variance (ANOVA) followed by Tukey’s test. In all cases, differences were considered statistically significant at p < 0.05. All statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Prism Software Inc., San Diego, CA, USA).

Results
Nar alleviates MTX-induced liver dysfunction in rats
The levels of serum ALT, AST, ALP and total bilirubin in the MTX group were significantly increased compared to those in the control group (Table 1). However, in the MTX + Nar groups, the abovementioned parameters significantly decreased compared to those of the MTX group. Indeed, the highest dose of Nar (80 mg/kg) markedly normalized the excessive levels of serum ALT, ALP and bilirubin induced by MTX.

Nar ameliorates MTX-induced hepatic oxidative stress in rats
The results of the oxidant status of the liver tissue are presented in Table 2. We found a significant reduction in SOD, CAT, GPX, GR and GSH in rats treated with MTX. Nar
administration inhibited the decrease in enzymatic activities and GSH levels in a dose-
dependent manner compared to the MTX administration. Interestingly, Nar at 80 mg/kg
restored CAT activity to normal levels. It was also evident that treatment with MTX
significantly increased MDA and iNO levels when compared to the “no treatment”
control. However, MDA and iNO levels were much lower in the MTX+Nar group than in
the MTX group.

Nar ameliorates MTX-induced proinflammatory cytokines in the rat liver
As shown in Table 3, the MTX-treated rats exhibited a significant increase in the levels
of hepatic TNF-α and IL-6 compared to the control rats. In contrast, Nar treatments
induced a significant decrease in the levels of these cytokines compared to MTX
treatment. In particular, the highest tested dose of Nar was more effective than the two
lower doses in reducing the elevated levels of IL-6 and TNF-α following MTX treatment.

Nar improves MTX-induced hepatocyte ultrastructural changes in rats
Electron microscopic examination of liver sections of control rats displayed normal
architecture (Fig. 1a). The cytoplasm of hepatocytes contained abundant mitochondria
with well-developed cristae. The rough endoplasmic reticulum (RER) consisted of
closely packed parallel and flattened cisternae. The nuclei appeared spherical with a
small amount of heterochromatin at the peripheral regions and a large central amount of
euchromatin. In the MTX group, RER cisternae of hepatocytes were fragmented, and
mitochondria were reduced and had ill-defined cristae, karyolysis was prominent, normal
structure was almost absent, and extensive fat droplets could be seen (Fig. 1b). Treatment
with Nar rescued the morphology of the hepatocytes and restored the cytoplasmic
organelles, more strongly with increasing dosage. Although slight degeneration was
observed in the cytoplasm of liver cells treated with low and medium doses of Nar, less
fragmented RER was observed, and mitochondria were well-protected (Fig. 1c-d). The
high dose of Nar significantly prevented ultrastructural damage to the hepatocytes (Fig.
1e).
Nar enhances the cytotoxicity of MTX against HepG2 cells

To investigate the effect of MTX and/or Nar on the growth inhibition of HepG2 cells, an MTT assay was employed. Compared with the respective untreated control cells, cells treated with increasing concentrations of MTX and/or Nar (12.5 μM - 3.2 mM) for 48 h exhibited decreased cell viability. As indicated in Figure 2a, compared to control cells, the significant decline in the viability of MTX- and/or Nar-treated HepG2 cells started after the treatment with the lowest doses of MTX and/or Nar (p < 0.01) and was significantly dose-dependent. MTX treatments exhibited more efficient inhibition (absolute IC\textsubscript{50} = 0.8 mM) viability than Nar treatments (absolute IC\textsubscript{50} = 2 mM).

Noticeably, the inhibition of the viability of HepG2 cells was significantly improved after cotreatment with MTX and Nar (absolute IC\textsubscript{50} = 0.3 mM for both) (Fig. 2b).

MTX and/or Nar induce morphological alterations in HepG2 cells

We evaluated the effect of MTX and/or Nar treatment on HepG2 cell morphology after a 48 h treatment period. The untreated cells showed a high confluency rate and normal monolayer formation compared to treated cells. The morphological changes of treated cells are shown in Figure 3. Morphological alterations and decreases in HepG2 cell dimensions and density were observed in treated cells when compared to control cells.

Treated cells exhibited a disturbed monolayer, swelling and rounded morphology with condensed chromatin; cells became shrunken, rounded in shape, showing blebbing and an increased number of floating cells, while untreated cells had an intact appearance.

Nar potentiates the MTX effect on the Bax/Bcl-2 ratio in HepG2 cells

To further investigate the effect of MTX and/or Nar on HepG2 cells, the expression levels of the proapoptotic protein Bax and the antiapoptotic protein Bcl-2, which are involved in proliferation, were evaluated. HepG2 cells were treated with the absolute IC\textsubscript{50} of Nar and/or MTX for 48 h. The general profile of cells after different treatments, increased Bax/Bcl-2 ratio, was similar when compared to control untreated cells.

Noticeably, the Bax/Bcl-2 ratio was significantly increased after cotreatment with MTX and Nar (Fig. 4).
Discussion

In this study, MTX-induced hepatotoxicity was manifested by a significant increase in the levels of serum ALT, AST and ALP enzymes. These enzymes are specific indicators of increased membrane permeability and/or necrotic damage in hepatocytes. In addition, MTX induced a concomitant increase in total bilirubin levels, which is also a clear marker of hepatic dysfunction. Liver injury was also confirmed by ultrastructural deformations in hepatocytes in the form of lipid infiltration, pyknotic or karyolysed nuclei, mitochondrial cristolysis and RER fragmentation. These changes are consistent with previous studies. Treatment of the MTX-administered rats with Nar significantly ameliorated all circulating liver function markers. In addition, Nar markedly protected cellular membranes and organelles with increasing doses, to the point that normal hepatocyte ultrastructure returned. Similar findings have been reported by Lv et al., who showed that Nar supplementation led to the resumption of elevated serum hepatic enzyme activities in perfluorooctane sulfonate-challenged mice. Another study by Zhou et al. reported that Nar reduced alcoholic hepatic steatosis, and the inhibitory effect was dose-dependent.

MTX can initiate hepatocellular oxidative damage through the excessive generation of ROS, mitochondrial dysfunction and deregulation of enzymatic or nonenzymatic antioxidant machinery. It has been reported that cytosolic NADP+-dependent dehydrogenases and NADP+-malic enzymes are inhibited by MTX, suggesting that the drug could decrease the availability of intracellular NADPH in cells, leading to depletion of cellular GSH and making cells more vulnerable to damage by ROS. ROS generation may lead to LPO and damage to cellular macromolecules, such as DNA, proteins, and lipid bilayers. Under the current experimental conditions, MTX administration induced a significant increase in LPO products (i.e., MDA) and a significant decrease in endogenous antioxidants, including GSH, CAT, SOD, GPx, and GR. This increase in redox imbalance was ameliorated by Nar treatment in a dose-dependent manner, possibly by its direct ability to scavenge free radicals or through the transcriptional upregulation of antioxidant genes. These results are consistent with reports of other investigators. Several studies have reported that the antioxidant and anti-inflammatory effects of Nar are retained up to 400 mg/kg exposure.
addition, Nar have a high safety margin towards cultured primary rat hepatocytes (IC$_{50}$ = 99.6 g/ml).\(^{44}\)

MTX administration has been shown to produce a significant increase in the levels of proinflammatory cytokines, such as TNF-α and IL-6, as well as \(\text{iNO}\) production.\(^{4,45}\) Excess \(\text{iNO}\) in the presence of superoxide anions may generate peroxynitrite radicals, cytotoxic prooxidants that causes protein nitration and cellular damage.\(^{46}\) In addition, excess \(\text{iNO}\) depletes intracellular GSH levels, thus increasing the susceptibility to oxidative stress.\(^{37}\) The results of the present study revealed that the increase in TNF-α, IL-6 and \(\text{iNO}\) levels was inhibited by Nar treatment when supplemented prior to and after MTX administration. This finding is consistent with previous studies.\(^{48,49}\)

\(\text{iNOS}\) is not constantly present in cells and accumulating evidences point out the involvement of \(\text{iNOS}\) in the production of NO when the cell is induced or stimulated, typically by proinflammatory cytokines and/or bacterial lipopolysaccharide. Upon induction, \(\text{iNOS}\) generates significant amounts of NO (micromolar range), which lasts sometimes for hours. Constitutive NOS (cNOS), by contrast, generate and release NO mainly in resting cells and produce nanomolar amounts of NO for short periods of time.\(^{50,51}\) Different experimental works have shown that cNOS activity is markedly inhibited by NO itself, whereas \(\text{iNOS}\) activity is highly resistant to inhibition by NO.\(^{52}\) It is well established that pro-inflammatory cytokines are potent inducers of \(\text{iNOS}\) in a wide variety of cells types, with consequent production of NO.\(^{53}\) The gene expression of \(\text{iNOS}\) and the subsequent mRNA translation are regulated by various stimuli, especially endogenous proinflammatory mediators such as TNF-α, IL-1β, IL-6, and IFN-γ. Hence, the expression of \(\text{iNOS}\) can only be induced by inflammatory stimuli and contribute to the large amount of NO production.\(^{50}\) The mechanism for the Nar anti-inflammatory action might involve the inhibition of NF-κB and \(\text{iNOS}\) signaling pathway.\(^{31,37}\)

Regardless of the combined efforts of governments and researchers globally, there has been a continuous rise in the incidence rate of hepatocellular carcinoma (HCC) during the last two decades.\(^{50,54}\) Towards the second aim of this study, HepG2 cells, as a model for HCC, were used to investigate the possible cytotoxic and antiproliferative effects of MTX and/or Nar. MTX and/or Nar provoked evident antitumor activity in
HepG2 cells, as assessed by in vitro cytotoxicity, morphological alterations, and the Bax/Bcl-2 protein expression ratio, which is consistent with what has been reported previously in vitro and in vivo.\textsuperscript{20,21} The reduction in the percentage of cell viability was dose-dependent following 48 h of treatment. The MTT results showed that MTX and/or Nar significantly inhibited the proliferation of HepG2 cells. Cells were more sensitive to MTX and Nar cotreatment (absolute IC\textsubscript{50} = 0.3 mM for each) than either MTX (absolute IC\textsubscript{50} = 0.8 mM) or Nar (absolute IC\textsubscript{50} = 2 mM) treatment alone. The treatment with MTX alone resulted in a non-typical growth inhibitory action on cancer cells with two concentration areas of inhibitory action: one below 10 µM and other above 1 mM. This most probably indicates two different inhibition mechanisms and/or two different targets. In case of the combined treatment of MTX+Nar, the inhibitory effect below 10 µM may be related to the action of MTX alone, whereas the inhibition around 1 mM may be caused by the combined action of both compounds. We did not investigate the effect of concentrations below 10 µM.

The induction of apoptosis is an important pathophysiological strategy through which an ideal antitumor agent acts to arrest cancer cell growth.\textsuperscript{5,24} Apoptosis is typically characterized by morphological alterations.\textsuperscript{5,24} Morphological examination of treated cells revealed apoptotic HepG2 cells with obvious changes in morphology, including cell shrinkage and nuclear chromatin condensation, implying the involvement of MTX and/or Nar, as reported previously.\textsuperscript{20}

Although the antiproliferative effect of Nar on HepG2 cells has been reported,\textsuperscript{19} the molecular mechanism involved remains unclear. Here, the immunoblotting analysis showed an upregulation of the proapoptotic Bax and downregulation of the antiapoptotic Bcl-2 upon treatment with MTX and/or Nar. The induction of apoptosis is a protective mechanism to eliminate neoplastic cells.\textsuperscript{5,24} Apoptosis may be initiated via the activation of the extrinsic or intrinsic pathways or both. Mitochondria are involved in the intrinsic apoptosis pathway. This apoptotic pathway is regulated by Bax, Bcl-2 and cytochrome c and eventually leads to the activation of caspase-3 and poly (ADP-ribose) polymerase (PARP).\textsuperscript{19,5,4} The activation of caspases is regulated by the fine balance of the ratios of Bax and Bcl-2 proteins,\textsuperscript{5,5} a mechanism that regulates the survival/apoptosis decision of a cell. The observed altered expression of Bax and Bcl-2 upon MTX and/or Nar treatment
of HepG2 cells in a manner that favors the increase in the Bax/Bcl-2 ratio could underlie the observed apoptotic effect and has been reported previously.\textsuperscript{19,20} The oligomerization of Bax on the outer mitochondrial membrane, as a result of excessive oxidative stress, leads to cytochrome c-release and degradation of Bcl-2. Here, while exposure to either MTX or Nar increased the Bax/Bcl-2 protein expression ratio, the combination of both treatments induced a more pronounced increase in the Bax/Bcl-2 ratio. This finding implies that the cotreatment of MTX and Nar synergistically aggravated their apoptotic effect in HepG2 cells. Many studies have reported that the deregulation of apoptosis-related proteins with a mechanism of action comparable to that of Nar, which further supports its role in apoptosis induction.\textsuperscript{20,24,60,61,62,63}

Nar can have a cytoprotective or apoptotic effect. Many studies have reported the apoptotic effect of Nar in different human cancer cell lines via various mechanisms and signaling pathways. Nar induces apoptosis in HeLa and HepG2 cells through activation of caspase-3, increased Bax/Bcl-2 ratio, and upregulation of miR-19b expression;\textsuperscript{19,20,21,23,62,64,65,66} in cervical cancer SiHa cells via death receptor and mitochondrial pathways;\textsuperscript{64} and in gastric adenocarcinoma AGS cells via autophagic cell death through downregulation of the PI3K/Akt/mTOR pathway, upregulation of p21, activation of Beclin 1 and LC3B, and phosphorylation MAPK.\textsuperscript{64}

**Conclusion**

In summary, the results of this experiment suggest that Nar can reverse MTX-induced hepatic damage through reduction of MDA, iNO, TNF-α, and IL-6 with the abrogation of cellular antioxidant defenses. Moreover, Nar potentiates the cytotoxic and anti-viability effect of MTX on HepG2 cancer cells. *In vivo* experiments using tumor-bearing animal models are required to determine if MTX and/or Nar are efficacious and safe for use as anticancer drugs.
Acknowledgments

The authors would like to thank the Deanship of Scientific Research at King Faisal University (Saudi Arabia) for financial support and providing grant funding to conduct this study (project no. 170046).

Authors’ contributions

HE, MK and AMA designed the experiments. HE and MK performed the biochemical and cell biological experiments. HE, AIA, MA, AS, OME and AMA performed the animal experiments. MA, AS, OME and AMA performed the electron microscopy investigations. All authors contributed toward data analysis, drafting and critically revising the paper, and approved the final version of the manuscript.

Declaration of conflicting interests

The authors declare that they have no conflicts of interest.

References

1. Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, et al. Chemotherapy for bladder cancer: Treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007;69:62-79.
2. Lukenbill J, Advani AS. The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Curr Hematol Malig R. 2013;8(2):91-7.
3. Bordbar M, Shakibazad N, Fattahi M, Haghpanah S, Honar N. Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia. Turk J Gastroenterol. 2018;29(2):203-9.
4. Abo-Haded HM, Elkablawy MA, Al-Johani Z, Al-ahmadi O, El-Agamy DS. Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity. Plos One. 2017;12(3):e0174295.
5. Hafez HM, Ibrahim MA, Ibrahim SA, Amin EE, Goma W, Abdelrahman AM. Potential protective effect of etanercept and aminoguanidine in methotrexate-induced hepatotoxicity and nephrotoxicity in rats. Eur J Pharmacol. 2015;768:1-12.
6. Liedtke C, Trautwein C. The role of TNF and Fas dependent signaling in animal models of inflammatory liver injury and liver cancer. Eur J Cell Biol. 2012;91(6-7):582-9.
7. Rao P, Hayden MS, Long MX, Scott ML, West AP, Zhang DK, et al. I kappa B beta acts to inhibit and activate gene expression during the inflammatory response. Nature. 2010;466(7310):1115-U132.
8. Cetiner M, Sener G, Sehirli AO, Eksioglu-Demiralp E, Erkan F, Sirvanci S, et al. Taurine protects against methotrexate-induced toxicity and inhibits leukocyte death. Toxicol Appl Pharmacol. 2005;209(1):39-50.
9. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651-65.
10. Leitao RFC, Brito GAC, Oria RB, Braga-Neto MB, Bellaguarda EAL, Silva JV, et al. Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents. BMC gastroenterology. 2011;11:90.
11. Gupta RK, Patel AK, Shah N, Choudhary AK, Jha UK, Yadav UC, et al. Oxidative Stress and Antioxidants in Disease and Cancer: A Review. Asian Pac J Cancer Prev. 2014;15(11):4405-9.
12. Sharma AK, Bharti S, Ojha S, Bhatia J, Kumar N, Ray R, et al. Up-regulation of PPAR gamma, heat shock protein-27 and -72 by naringin attenuates insulin resistance, beta-cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes. Brit J Nutr. 2011;106(11):1713-23.
13. Lee MH, Yoon S, Moon JO. The flavonoid naringenin inhibits dimethylnitrosamine-induced liver damage in rats. Biol Pharm Bull. 2004;27(1):72-6.
14. Erdogan S, Doganlar O, Doganlar ZB, Turkekul K. Naringin sensitizes human prostate cancer cells to paclitaxel therapy. Prostate Int. 2018;6(4):126-35.
15. Mahmoud AM, Ashour MB, Abdel-Moneim A, Ahmed OM. Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats. J Diabetes Complicat. 2012;26(6):483-90.
16. El-Desoky AH, Abdel-Rahman RF, Ahmed OK, El-Beltagi HS, Hattori M. Anti-inflammatory and antioxidative activities of naringin isolated from Carissa carandas L.: In vitro and in vivo evidence. Phytomedicine. 2018;42:126-34.
17. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2018;68(6):394-424.
18. Liang J, Wang CY, Peng JY, Li WS, Jin Y, Liu Q, et al. Naringin regulates cholesterol homeostasis and inhibits inflammation via modulating NF-kappa B and ERK signaling pathways in vitro. Pharmazie. 2016;71(2):101-8.
19. Banjerdpongchai R, Wudtiwai B, Khawon P. Induction of Human Hepatocellular Carcinoma HepG2 Cell Apoptosis by Naringin. Asian Pac J Cancer Prev. 2016;17(7):3289-94.
20. Xie DF, Yuan PW, Wang D, Jin H, Chen H. Effects of naringin on the expression of miR-19b and cell apoptosis in human hepatocellular carcinoma. Oncol Lett. 2017;14(2):1455-9.
17. Shen W, Xu Y, Lu YH. Inhibitory Effects of Citrus Flavonoids on Starch Digestion and Antihyperglycemic Effects in HepG2 Cells. *J Agr Food Chem.* 2012;60(38):9609-19.

22. Zhang JK, Sun CD, Yan YY, Chen QJ, Luo FL, Zhu XY, et al. Purification of naringin and neohesperidin from Huyou (*Citrus changshanensis*) fruit and their effects on glucose consumption in human HepG2 cells. *Food Chem.* 2012;135(3):1471-8.

23. Mohamed EA, Abu Hashim II, Yusif RM, Shaaban AAA, EI-Sheakh AR, Hamed MF, et al. Polymeric micelles for potentiated antiulcer and anticancer activities of naringin. *Int J Nanomed.* 2018;13:1009-27.

24. Golechha M, Sarangal V, Bhatia J, Chaudhry U, Saluja D, Arya DS. Naringin ameliorates pentylenetetrazol-induced seizures and associated oxidative stress, inflammation, and cognitive impairment in rats: Possible mechanisms of neuroprotection. *Epilepsy Behav.* 2014;41:98-102.

25. Armagan I, Bayram D, Candan IA, Yigit A, Anagann HH, et al. Effects of pentoxifylline and alpha lipoic acid on methotrexate-induced damage in liver and kidney of rats. *Environ Toxicol Phar.* 2015;39(3):1122-31.

26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.* 1976;72:248-54.

27. David AVA, Satyanarayana N, Parasuraman S, Bharathi S, Arulmoli R. Ameliorative Effect of Quercetin on Methotrexate Induced Toxicity in Sprague-Dawley Rats: A Histopathological Study. *Indian J Pharm Educ.* 2016;50(3):S200-S8.

28. Renugadevi J, Prabu SM. Cadmium-induced hepatotoxicity in rats and the protective effect of naringenin. *Exp Toxicol Pathol.* 2010;62(2):171-81.

29. Zhou C, Lai Y, Huang P, Xie L, Lin H, Zhou Z, et al. Naringin attenuates alcoholic liver injury by reducing lipid accumulation and oxidative stress. *Life Sci.* 2019;216:305-12.

30. Vardi N, Parlakpinar H, Cetin A, Erdogan A, Cetin Ozturk I. Protective effect of beta-carotene on methotrexate-induced oxidative liver damage. *Toxicol Pathol.* 2010;38(4):592-7.

31. Mehrzadi S, Fatemi I, Esmaeilizadeh M, Ghaznavi H, Kalantar H, Goudarzi M. Hepatoprotective effect of berberine against methotrexate induced liver toxicity in rats. *Biomed Pharmacother.* 2018;97:233-9.
Damage: Alleviation by N-Acetylcysteine and N-Acetylcysteine Amide. *Plos One.* 2015;10(6):e0127558.

36. Moskovitz J, Yim MB, Chock PB. Free radicals and disease. *Arch Biochem Biophys.* 2002;397(2):354-9.

37. Chtourou Y, Aouey B, Kebieche M, Fetoui H. Protective role of naringin against cisplatin induced oxidative stress, inflammatory response and apoptosis in rat striatum via suppressing ROS-mediated NF-κB and P53 signaling pathways. *Chem-Biol Interact.* 2015;239:76-86.

38. Jeon SM, Bok SH, Jang MK, Lee MK, Nam KT, Park YB, et al. Antioxidative activity of naringin and lovastatin in high cholesterol-fed rabbits. *Life Sci.* 2001;69(24):2855-66.

39. Adil M, Kandhare AD, Ghosh P, Bodhankar SL. Sodium arsenite-induced myocardial bruise in rats: Ameliorative effect of naringin via TGF-beta/Smad and Nrf/HO pathways. *Chem-Biol Interact.* 2016;253:66-77.

40. Nzuza S, Owira P. Naringin abrogates HIV-1 protease inhibitors-induced atherogenic dyslipidemia and oxidative stress in vivo. *J Funct Foods.* 2019;52:156-64.

41. Jung UJ, Kim HJ, Lee JS, Lee MK, Kim HO, Park EJ, et al. Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects. *Clin Nutr.* 2003;22(6), 561-8.

42. Jagetia GC, Reddy TK, Venkatesha VA, Kedlaya R. Influence of naringin on ferric iron induced oxidative damage in vitro. *Clin Chim Acta.* 2004:347(1-2):189-97.

43. Singh D, Chopra K. The effect of naringin, a bioflavonoid on ischemia-reperfusion induced renal injury in rats. *Pharmacol Res.* 2004;50:187-93.

44. El-Desoky AH, Abdel-Rahman RF, Ahmed OK, El-Beltagi HS, Hattori M. Anti-inflammatory and antioxidant activities of naringin isolated from *Carissa carandas* L.: In vitro and in vivo evidence. *Phytomedicine.* 2018;42,126-34.

45. Abdel-Daim MM, Khalifa HA, Abushouk AL, Dkhil MA, Al-Quraishy SA. Diosmin Attenuates Methotrexate-Induced Hepatic, Renal, and Cardiac Injury: A Biochemical and Histopathological Study in Mice. *Oxid Med Cell Longev.* 2017;2017:3281670.

46. Groeneveld PHP, Kwappenberg KMC, Langermans JAM, Nibbering PH, Curtis L. Nitric oxide (NO) production correlates with renal insufficiency and multiple organ dysfunction syndrome in severe sepsis. *Intensive Care Med.* 1996;22(11):1197-202.

47. Jung M, Hotter G, Viñas JL, Sola A. Cisplatin upregulates mitochondrial nitric oxide synthase and peroxynitrite formation to promote renal injury. *Toxicol Appl Pharm.* 2009;234(2):236-46.

48. Xianchhu L, Lan PZ, Qiufang L, Yi L, Xiangcheng R, Wenqi H, et al. Naringin protects against lipopolysaccharide-induced cardiac injury in mice. *Environ Toxicol Phar.* 2016;48:1-6.

49. Gelen V, Şengül E, Yıldırım S, Atila G. The protective effects of naringin against 5-flourouracil-induced hepatotoxicity and nephrotoxicity in rats. *Iran J Basic Med Sci.* 2018;21(4):404-10.

50. Yu X, Ge L, Niu L, Lian X, Ma H, Pang L. The dual role of inducible nitric oxide synthase in myocardial ischemia/reperfusion injury: friend or foe? Oxidative medicine and cellular longevity. 2018; Article ID 8364848:7 pages.
51. Cinelli MA, Do HT, Miley GP, Silverman RB. Inducible nitric oxide synthase: Regulation, structure, and inhibition. Medicinal research reviews. 2020;40(1):158-289.
52. Cernadas MR, de Miguel LS, García-Durán M, González-Fernández F, Millás I, Montón M, Rodrigo J, Rico L, Fernández P, de Frutos T, Rodríguez-Feo JA. Expression of constitutive and inducible nitric oxide synthases in the vascular wall of young and aging rats. Circulation Research. 1998;83(3):279-86.
53. Leitão RF, Brito GA, Oriá RB, Braga-Neto MB, Bellaguarda EA, Silva JV, Gomes AS, Lima-Júnior RC, Siqueira FJ, Freire RS, Vale ML. Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents. BMC gastroenterology. 2011;11(1):90.
54. Alwhibi MS, Khalil MIM, Ibrahim MM, El-Gaaly GA, Sultan AS. Potential Antitumor Activity and Apoptosis Induction of Glossostemon bruguieri Root Extract against Hepatocellular Carcinoma Cells. Evid-Based Compl Alt. 2017;2017:7218562.
55. Bonavida B, Garban H. Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics. Redox Biol. 2015;6:486-94.
56. Sultan AS, Khalil MIM, Sami BM, Alkhuriji AF, Sadek O. Quercetin induces apoptosis in triple-negative breast cancer cells via inhibiting fatty acid synthase and beta-catenin. Int J Clin Exp Patho. 2017;10(1):156-72.
57. Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol. 2013;25(1):50-1.
58. Zhu L, Han MB, Gao Y, Wang H, Dai L, Wen Y, et al. Curcumin triggers apoptosis via upregulation of Bax/Bcl-2 ratio and caspase activation in SW872 human adipocytes. Mol Med Rep. 2015;12(1):1151-6.
59. Liu Z, Ding Y, Ye N, Wild C, Chen H, Zhou J. Direct Activation of Bax Protein for Cancer Therapy. Med Res Rev. 2016;36(2):313-41.
60. Arumugam S, Girish Subbiah K, Kemparaju K, Thirunavukkarasu C. Neutrophil extracellular traps in acrolein promoted hepatic ischemia reperfusion injury: Therapeutic potential of NOX2 and p38MAPK inhibitors. J Cell Physiol. 2018;233(4):3244-61.
61. Chen JY, Wu CL, Liu JF, Fong YC, Hsu SF, Li TM, et al. Honokiol induces cell apoptosis in human chondrosarcoma cells through mitochondrial dysfunction and endoplasmic reticulum stress. Cancer Lett. 2010;291(1):20-30.
62. Arul D, Subramanian P, Naringenin (Citrus Flavonone) Induces Growth Inhibition, Cell Cycle Arrest and Apoptosis in Human Hepatocellular Carcinoma Cells. Pathol Oncol Res. 2013;19(4):763-70.
63. Zeng L, Zhen Y, Chen Y, Zou L, Zhang Y, Hu F, et al. Naringin inhibits growth and induces apoptosis by a mechanism dependent on reduced activation of NFkappaB/COX2/caspase-1 pathway in HeLa cervical cancer cells. Int J Oncol. 2014;45(5):1929-36.
64. Ramesh E, Alshatwi AA. Naringin induces death receptor and mitochondria-mediated apoptosis in human cervical cancer (SiHa) cells. Food Chem Toxicol. 2013;51:97-105.
65. Raha S, Yumnam S, Hong GE, Lee HJ, Saralamma VV, Park HS, et al. Naringin induces autophagy-mediated growth inhibition by downregulating the
PI3K/Akt/mTOR cascade via activation of MAPK pathways in AGS cancer cells. *Int J Oncol.* 2015;47(3):1061-9.

Legends of figures:

**Figure 1:** Representative transmission electron micrographs of rat hepatocytes. (a) Control, (b) MTX, (c) MTX+Nar20, (d) MTX+Nar40, and (e) MTX+Nar80. N = Nucleus, M = Mitochondria, RER = Rough Endoplasmic Reticulum, and L = Lipid droplet.

**Figure 2:** Nar enhanced the cytotoxicity of MTX against HepG2 cells. Cells were treated with increasing concentrations of Nar and/or MTX (12.5 μM - 3.2 mM) for 48 h. Controls were treated with DMSO only. (a) The effects of MTX and/or Nar on the proliferation of HepG2 cells are expressed as a percentage of cell viability; (b) A semilogarithmic plot of the cell viability percentage of HepG2 cells over the 48 h exposure to increasing concentrations of MTX and/or Nar. IC$_{50}$; absolute IC$_{50}$ is the concentration that corresponds to 50% inhibition of the viability of HepG2 cells. Data from at least three independent experiments performed in at least triplicate are presented as the means ± SEM, *p < 0.01 vs. control group.

**Figure 3:** MTX- and/or Nar-induced morphological alterations in HepG2 cells. Cells were plated in 12-well plates and treated with the absolute IC$_{50}$ of MTX and/or Nar for 48 h. The photographs were taken from culture plates using a phase contrast microscope at ×400 magnification. Control cells were treated with DMSO only. Representative pictures are shown from three independent experiments.

**Figure 4:** Bax and Bcl-2 expression levels and Bax/Bcl-2 ratio in MTX and/or Nar-treated HepG2 cells. Cells were plated in 6-well plates and treated with the absolute IC$_{50}$ of MTX and/or Nar for 48 h. (a) Expression levels of Bax and Bcl-2 in HepG2 cells; (b) Bax/Bcl-2 ratio in HepG2 cells. Data from at least three independent experiments are presented as the means ± SE, *Significant difference with control (**p < 0.01). §Significant difference with the MTX group (**p < 0.01). §Significant difference with the Nar group (p< 0.05).
Table 1: Effect of Nar on liver function enzymes and bilirubin level in MTX-treated rats.

| Groups     | ALT (U/L) | AST (U/L) | ALP (U/L) | Bilirubin (mg/dl) |
|------------|-----------|-----------|-----------|-------------------|
| Control    | 38.8± 3.8 | 53.0± 7.1 | 43.7± 7.2 | 0.3± 0.0          |
| MTX        | 77.3± 9.8 | 157.2± 15.8 | 112.0± 8.5 | 0.8± 0.1          |
| MTX+Nar20  | 54.0± 5.7 | 100.6± 13.3 | 80.4± 3.5 | 0.5± 0.1          |
| MTX+Nar40  | 51.2± 4.8 | 98.7± 7.9 | 74.3± 5.1 | 0.6± 0.1          |
| MTX+Nar80  | 36.0± 3.5 | 70.8± 3.7 | 50.0± 2.5 | 0.37± 0.0         |

Data are presented as mean ± SE (n=6).

Mean values with different superscript letters in the same column are significantly different at $p < 0.05$. 
Table 2: Effect of Nar on oxidative stress parameters in MTX-treated rats.

| Groups       | MDA nmol/g tissue | GSH µmol/g tissue | CAT U/mg protein | SOD U/mg protein | GPx mU/mg protein | GR U/mg protein | Nitrite (NO) µmol/g tissue |
|--------------|-------------------|-------------------|------------------|------------------|------------------|----------------|---------------------------|
| Control      | 8.4<sup>d</sup> ± 0.1 | 43.7<sup>a</sup> ± 1.4 | 44.0<sup>b</sup> ± 1.1 | 64.0<sup>a</sup> ± 1.0 | 68.8<sup>a</sup> ± 1.3 | 56.2<sup>a</sup> ± 0.9 | 6.4<sup>d</sup> ± 0.1 |
| MTX          | 36.4<sup>a</sup> ± 1.0 | 19.0<sup>d</sup> ± 1.5 | 22.8<sup>c</sup> ± 1.5 | 30.2<sup>d</sup> ± 0.9 | 32.0<sup>d</sup> ± 1.6 | 25.8<sup>d</sup> ± 1.7 | 21.2<sup>a</sup> ± 0.8 |
| MTX+Nar20    | 26.3<sup>b</sup> ± 1.5 | 26.0<sup>c</sup> ± 1.2 | 35.2<sup>b</sup> ± 1.1 | 42.3<sup>c</sup> ± 1.2 | 44.0<sup>c</sup> ± 1.1 | 35.7<sup>c</sup> ± 1.7 | 14.7<sup>b</sup> ± 0.7 |
| MTX+Nar40    | 24.7<sup>b</sup> ± 1.5 | 25.0<sup>c</sup> ± 1.5 | 33.3<sup>b</sup> ± 1.3 | 47.2<sup>c</sup> ± 1.0 | 46.0<sup>c</sup> ± 1.8 | 39.0<sup>c</sup> ± 1.3 | 12.5<sup>b</sup> ± 0.6 |
| MTX+Nar80    | 19.8<sup>c</sup> ± 1.3 | 31.5<sup>b</sup> ± 1.0 | 40.5<sup>d</sup> ± 1.3 | 58.7<sup>b</sup> ± 1.1 | 53.3<sup>b</sup> ± 1.7 | 49.0<sup>b</sup> ± 1.5 | 9.1<sup>c</sup> ± 0.7 |

Data are presented as mean ± SE (n=6).

Mean values with different superscript letters in the same column are significantly different at <i>p</i> <0.05.
Table 3: Effect of Nar on pro-inflammatory cytokines in MTX-treated rats.

| Groups        | TNF-α (pg/ml) | IL-6 (pg/ml) |
|---------------|---------------|--------------|
| Control       | 45.2±1.1      | 63.3±0.6     |
| MTX           | 146.2±1.3     | 166.2±0.8    |
| MTX+Nar20     | 75.7±1.2      | 86.7±1.2     |
| MTX+Nar40     | 78.8±0.6      | 83.2±1.4     |
| MTX+Nar80     | 57.8±1.2      | 74.7±0.8     |

Data are presented as mean ± SE (n=6).

Mean values with different superscript letters in the same column are significantly different at $p < 0.05$. 
(a) Western blot analysis showing the expression levels of Bax, Bcl-2, and β-actin proteins in different treatment groups: Control, MTX, Nar, and MTX+Nar.

(b) Bar graph representing the Bax/Bcl-2 ratio (relative to control) for each treatment group. Statistical significance is marked with asterisks: * for p < 0.05 and ** for p < 0.01.